Covid-fighting drug from S.F. biotech fizzles in late-stage trial

Enrollment in the NIH trial was stopped, but other studies of the drug are continuing, the companies said.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.